Metagenomi Therapeutics Inc's Comment on Supply Chain
The company utilizes raw materials derived from biological sources in its manufacturing processes. These materials can be challenging to obtain and may be subject to contamination or recall, potentially disrupting manufacturing and clinical material production, which could impact development timelines and business outcomes. Manufacturing issues, including those occurring at third-party facilities, may limit the availability of clinical trial materials and market supply. The company operates in a competitive genome editing landscape, facing competition from pharmaceutical and biotechnology companies, academic institutions, and government agencies. Competitors employ various scientific approaches, including CRISPR/Cas technology and alternative genome editing methods.
Suppliers referenced in company filings include Beam Therapeutics, Caribou Biosciences, Inc., Cellectis Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Eli Lilly and Company, Intellia Therapeutics, Inc., Precision BioSciences, Inc., Prime Medicine, Sangamo Therapeutics, Inc., and Verve Therapeutics, Inc.
Metagenomi Therapeutics Inc's Comment on Supply Chain
The company utilizes raw materials derived from biological sources in its manufacturing processes. These materials can be challenging to obtain and may be subject to contamination or recall, potentially disrupting manufacturing and clinical material production, which could impact development timelines and business outcomes. Manufacturing issues, including those occurring at third-party facilities, may limit the availability of clinical trial materials and market supply. The company operates in a competitive genome editing landscape, facing competition from pharmaceutical and biotechnology companies, academic institutions, and government agencies. Competitors employ various scientific approaches, including CRISPR/Cas technology and alternative genome editing methods.
Suppliers referenced in company filings include Beam Therapeutics, Caribou Biosciences, Inc., Cellectis Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Eli Lilly and Company, Intellia Therapeutics, Inc., Precision BioSciences, Inc., Prime Medicine, Sangamo Therapeutics, Inc., and Verve Therapeutics, Inc.
Sources:
Metagenomi Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Metagenomi Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
